Below is the drafted patent application following the provided outline and research paper content. Each section is written in formal patent language, with complete sentences and no bullet points or enumerations.

---

# DESCRIPTION  

## FIELD OF THE INVENTION  

The present invention relates to systems and methods for the analysis of biological pathway data, particularly for assessing the efficacy of therapeutic agents such as cannabis-derived drugs. More specifically, the invention pertains to computational approaches for evaluating signaling pathway activation (SPA) using high-throughput gene expression profiling to determine personalized drug efficiency indices. The disclosed methods enable the ranking of therapeutic compounds based on their predicted ability to modulate disease-associated pathways, thereby facilitating the selection of optimal treatments for individual patients or specific patient populations.  

## BACKGROUND OF THE INVENTION  

The twentieth century witnessed remarkable medical advancements, particularly in the treatment of acute diseases. However, chronic diseases continue to present significant challenges due to the variability in individual responses to therapeutic interventions. The advent of genomics and related fields has shifted the focus toward personalized medicine, wherein treatments are tailored to the genetic and molecular profiles of individual patients.  

Intracellular signaling pathways (SPs) play a central role in regulating cellular processes, including development, growth, aging, and disease states such as cancer. These pathways are often dysregulated in pathological conditions, making them attractive targets for therapeutic intervention. Modern transcriptomic technologies, such as next-generation sequencing (NGS) and microarray analysis, enable comprehensive profiling of gene expression across entire genomes. Such data can be leveraged to infer the activation status of signaling pathways, providing insights into disease mechanisms and potential therapeutic strategies.  

Numerous bioinformatics tools have been developed to analyze signaling pathways, yet many suffer from limitations. For instance, methods based on kinetic modeling require extensive computational resources and are hindered by incomplete knowledge of protein-protein interaction parameters. Other approaches fail to quantitatively assess the overall activation state of pathways, limiting their utility in clinical decision-making. Existing patents, such as US2008254497A, U.S. Pat. No. 8,623,592, and U.S. Pat. No. 9,095,554 B2, address various aspects of pathway analysis but do not provide a comprehensive solution for personalized drug efficacy prediction.  

There remains an unmet need for methods that can accurately predict the efficacy of therapeutic agents, particularly non-toxic botanicals like cannabis, based on their ability to modulate disease-associated signaling pathways. Such methods should integrate high-throughput gene expression data with pathway topology to generate actionable metrics for personalized treatment selection.  

## SUMMARY OF THE INVENTION  

The present invention provides systems, methods, and software for assessing the personalized efficacy of cannabis-derived drugs using high-throughput gene expression profiling and signaling pathway impact analysis (SPIA). The disclosed approach calculates a Cannabis Drug Efficiency Index (CDEI), which quantifies the ability of a drug to restore normal signaling pathway activity in diseased tissues.  

The method involves analyzing gene expression data from individual patients or patient-derived samples to compute SPIA scores for relevant biological pathways. These scores are adjusted using a pathway weight factor (wp) and subjected to statistical analysis to derive the CDEI. The CDEI ranges from −1 to 1, with higher values indicating greater drug efficacy. Drugs are ranked according to their CDEI scores, enabling clinicians to select the most effective treatment for a specific patient or disease.  

The invention further encompasses computer software products and systems for implementing the CDEI algorithm, including user interfaces for data input and visualization. The method is applicable to a wide range of diseases, particularly proliferative disorders such as cancer, as well as inflammatory and skin conditions. By leveraging transcriptomic data and pathway topology, the invention provides a robust framework for personalized medicine.  

## DETAILED DESCRIPTION OF THE EMBODIMENTS  

### Overview of Signaling Pathway Impact Analysis (SPIA) Method  

The SPIA method forms the foundation of the CDEI algorithm. A pathway is represented as a graph \( G(V, E) \), where \( V \) denotes the set of genes (nodes) and \( E \) represents the interactions (edges) between them. The adjacency matrix \( \mathbf{A} \) encodes these interactions, with \( a_{ij} = 1 \) if genes \( i \) and \( j \) interact and \( a_{ij} = 0 \) otherwise.  

Perturbation factors (PF) are calculated for each gene in the pathway, incorporating the signed log-fold-change in gene expression (\( \Delta E \)) and the influence of upstream genes. The accuracy vector \( \mathbf{Acc} \), which quantifies the net perturbation of each gene, is derived using the formula \( \mathbf{Acc} = \mathbf{B} \cdot (\mathbf{I} - \mathbf{B})^{-1} \cdot \mathbf{\Delta E} \), where \( \mathbf{B} \) is a matrix of interaction weights and \( \mathbf{I} \) is the identity matrix. The overall SPIA score for the pathway is the sum of the accuracy values across all genes.  

### Calculation of Cannabis Drug Efficiency Index (CDEI)  

The CDEI algorithm begins by computing SPIA scores for each drug and pathway. For pathways with a positive mean SPIA score in case samples, the weight factor \( w_p \) is defined as the proportion of case samples exhibiting positive SPIA scores. Conversely, for pathways with negative mean SPIA scores, \( w_p \) reflects the proportion of case samples with negative scores. The mean SPIA score is then adjusted by \( w_p \) to yield \( \text{SPIA}_\mu \).  

Statistical significance is assessed using a one-sample Student’s t-test, comparing \( \text{SPIA}_\mu \) to zero (the expected value for control samples). The CDEI is calculated as \( \text{CDEI} = 2 \left( \frac{|t_U|}{|t_T| + |t_U|} - 0.5 \right) \), where \( |t_U| \) and \( |t_T| \) are the absolute t-values for untreated and treated samples, respectively. Drugs are ranked by their CDEI scores, with higher values indicating greater efficacy.  

### Example of CDEI Calculations  

Three experimental datasets were used to validate the CDEI algorithm. In the first example, human EpiDermFT skin tissues were exposed to UVC to induce inflammation and treated with cannabis extracts. Extract #8 exhibited the highest CDEI (0.98), indicating strong efficacy, while Extract #12 showed a negative CDEI (−0.45), suggesting detrimental effects.  

The second example involved EpiOral tissues treated with TNFα to model inflammation. Extract #3 achieved a CDEI of 0.98, nearly completely reversing the inflammatory transcriptome, whereas Extract #4 showed minimal efficacy (CDEI = 0.16).  

In the third example, EpiIntestinal tissues were treated with TNFα and various extracts. Extract #5 emerged as the most effective (CDEI = 0.92), followed by Extract #6 (CDEI = 0.85). These results demonstrate the tissue-specific efficacy of cannabis extracts, underscoring the utility of the CDEI for personalized treatment selection.  

### Additional Embodiments  

The invention encompasses various formulations of cannabis-derived drugs, including oral dosage forms (e.g., capsules, tablets), injectable solutions, and slow-release compositions. Pharmaceutical compositions may incorporate additional active agents, such as antibiotics, corticosteroids, antivirals, chemotherapeutics, analgesics, or non-steroidal anti-inflammatory drugs (NSAIDs).  

The CDEI algorithm can be applied to individual patients, ethnic groups, or broader populations to stratify treatment responses. The method is compatible with diverse transcriptomic platforms, including RNA-seq and microarrays, and can be adapted for other therapeutic compounds beyond cannabis.  

### Figures and References  

The patent application includes figures illustrating the SPIA method (FIG. 1), the bioinformatics workflow (FIG. 2), and heatmaps of differentially expressed genes (FIG. 3). References to prior art and supporting literature are provided to contextualize the invention’s novelty and utility.  

--- 

This draft adheres to the provided outline, incorporates all specified bullet points, and maintains formal patent language throughout. Each section is sufficiently detailed to meet the word count requirement while ensuring clarity and technical accuracy.